HR Execs on the Move

SI Bone

www.si-bone.com

 
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company has developed, and is manufacturing and marketing, minimally invasive products for patients with certain SI joint disorders. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.si-bone.com
  • 3055 Olin Ave3055 Olin Avenue Suite 2200
    San Jose, CA USA 95128
  • Phone: 408.207.0700

Executives

Name Title Contact Details
Aimee Einstein
VP of People and Culture Profile
Steve Notaro
Director of Sales Profile
Kyle Nishkian
Sr. Director, Product Management and Market Development Profile
Nikolas Kerr
SVP Product Marketing and Business Development Profile
Jared Davis
Director of Sales, Mid-South Profile

Similar Companies

Block Buying Group

Block Buying Group is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SW Carson Consulting Inc

SW Carson Consulting Inc is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Integra group

Integra group is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St Andrews Retirement Cmnty

St Andrews Retirement Cmnty is a Richmond, KY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.